Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

37 results about "SECRETOR FACTOR" patented technology

Method for extracting paracrine factor from adipose-derived stem cells

PendingCN112080465AStable karyotypeStable extraction efficiencyPeptide preparation methodsSkeletal/connective tissue cellsCD29Digestion
The invention discloses a method for extracting a paracrine factor from adipose-derived stem cells. The method comprises the following steps: taking a collected fat sample, and washing the fat samplewith normal saline for 1-3 times; adding a proper amount of adipose cell digestive juice for digestion; performing centrifugation, resuspending cell precipitate, and performing primary culture with aserum-free medium; performing subculture; performing enlarged culture; and performing extraction with a paracrine factor extracting solution, and performing purification to obtain the paracrine factor, wherein the paracrine factor extracting solution is prepared from a PBS buffer solution, L-glutamine, D-glucose and L-ascorbic acid, and the concentrations of the L-glutamine, the D-glucose and theL-ascorbic acid are 1-3mmol/L, 10-20 micromoles/L and 10-100 micromoles/L respectively. The method disclosed by the invention can stably extract the adipose-derived stem cells from adipose tissues, and extract the paracrine factor of the adipose-derived stem cells by utilizing the adipose-derived stem cells, so that the cell quality and the factor extraction efficiency are stable; and the adipose-derived stem cells are separated and cultured for a long time in a GMP environment, do not contact any animal-derived component, and can efficiently express adipose-derived stem cell markers such as CD29, CD44 and CD105.
Owner:北京银丰鼎诚生物工程技术有限公司

Externally-applied medicine for treating cutaneous appendages and skin pruritic disease and preparation method and application thereof

The invention discloses an externally-applied medicine for treating cutaneous appendages and skin pruritic disease and a preparation method and application thereof. The main component of the medicine is an NK cell stock solution which is obtained by amplifying and culturing NK cells. The NK cell stock solution is mixed with different medicine auxiliaries, and an externally-applied liquid preparation or externally-applied paste preparation can be prepared. Compared with the prior art, the externally-applied medicine can be directly used for treating acne, seborrheic dermatitis, pruritus, prurigo nodularis and other cutaneous appendages and skin pruritic disease and is rapid in treatment effect and meanwhile can improve the skin immune system and repair damaged skin according to the characteristics that protein and cell factors secreted by the NK cells can be easily absorbed by skin and can directly act on target cells. Secreted factors in the NK cell stock solution can kill fungi and bacteria, and the medicine achieves the aim of comprehensively treating acne, dermatitis and pruritus, is wide treatment range and can prevent repeated aggravation of pathogenetic conditions.
Owner:SHANGHAI MINGDA BIOTECH CO LTD

Mesenchymal stem cell substitute product containing degradable biomedical sustained-release material and application thereof

The invention discloses a mesenchymal stem cell substitute product containing a degradable biomedical sustained-release material and application thereof. The mesenchymal stem cell substitute product comprises the following ingredients (by weight): 1-5% of the degradable biomedical sustained-release material, 0.1-5% of a mesenchymal stem cell secreted factor and the balance an electrolyte injection. The degradable biomedical sustained-release material is a medicinal raw material with plasticity, biocompatibility, histocompatibility and degradation product safety. The sustained-release materialis processed into slow-release gel or sustained-release microspheres wit different particle sizes. By a swelling blending method and/or a high voltage electrostatic method, the prepared ''mesenchymalstem cell paracrine mimetic'' containing the biomedical sustained-release material and the secreted factor has good biocompatibility and slow release performance, has no cytotoxicity, can promote corresponding cell proliferation, has good freeze-drying stability, can be directly stored at low temperature, is convenient to store and transport, helps reduce pollution risk caused by man-made operation, and can be directly used after being unfrozen.
Owner:TIANJIN AMCELLGENE ENG

Preparation method of paracrine factor inclusion with skin cell rejuvenation effect

The invention discloses a preparation method of a paracrine factor inclusion with a skin cell rejuvenation effect. The preparation method comprises the following steps of: step a, putting an umbilical cord into a storage and transportation bottle containing a storage and transportation liquid for later separation and preparation; b, placing the umbilical cord into a culture dish, fully washing the umbilical cord with normal saline, cutting off 1cm of the two ends of the umbilical cord, repeatedly washing the umbilical cord tissue until no obvious blood clots exist, cutting the umbilical cord into small sections with the length of 2cm, washing for three times, longitudinally splitting the umbilical cord, removing blood vessels, tearing off Wharton's jelly, fully washing the Wharton's jelly with normal saline for three times, and then cutting the tissue into tissue blocks with the size of 1-3 cubic millimeters. According to the method, the paracrine factors of the mesenchymal stem cells are wrapped with the microcapsules, can be stored at normal temperature and have stable properties, and the microcapsule inclusion and the fibroblasts are co-cultured, so that the increase of collagen secreted by the fibroblasts can be improved, the division activity can be improved, and the service life of the fibroblasts can be prolonged.
Owner:朱瑜

Application of vascular secretion factor in preparation of biomarker for detecting non-alcoholic steatohepatitis

ActiveCN114525329APrevent regenerationInhibition induced fibrosisOrganic active ingredientsMetabolism disorderFatty liverHistone deacetylase 2
The invention belongs to the field of biological medicine, and mainly relates to application of a vascular secretion factor in preparation of a biomarker for detecting non-alcoholic steatohepatitis. The invention provides an application of a vascular secretion factor in preparation of a biomarker for detecting non-alcoholic steatohepatitis, and is characterized in that the vascular secretion factor comprises IGFBP7 and/or ADAMTS1; the IGFBP7 and/or the ADAMTS1 are/is expressed in an HDAC2 (histone deacetylase 2)/DNMT1-IGFBP7/ADAMTS1-Th17 signal channel. The invention also provides application of the vascular secretion factor in preparation of the biomarker for distinguishing the non-alcoholic steatohepatitis and the simple fatty liver, and is characterized in that the vascular secretion factor comprises IGFBP7 and/or ADAMTS1; the IGFBP7 and/or the ADAMTS1 are/is expressed in an HDAC2 (histone deacetylase 2)/DNMT1-IGFBP7/ADAMTS1-Th17 signal channel. The invention further provides application of the synergistic effect of the IGFBP7 and/or the ADAMTS1 in preparation of the biomarker for detecting the non-alcoholic steatohepatitis. According to the application provided by the invention, the non-alcoholic steatohepatitis can be evaluated more reliably, simply, conveniently and noninvasively.
Owner:THE WEST CHINA SECOND UNIV HOSPITAL OF SICHUAN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products